These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16998554)

  • 21. Reversible edema in a male patient taking parenteral pantoprazole infusion for pyloric stenosis.
    Sennaroglu E; Karakan S; Kayatas M; Akdur S; Genc H; Karakan T; Ucler R; Ozisler C; Urun Y
    Dig Dis Sci; 2006 Jan; 51(1):121-2. PubMed ID: 16416223
    [No Abstract]   [Full Text] [Related]  

  • 22. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomics of proton pump inhibitors.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [All proton pump inhibitors are equally efficacious in standard dosages].
    Hellström PM; Vitols S
    Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proton-pump inhibitors: three of a kind?
    Bateman DN
    Lancet; 1997 Jun; 349(9066):1637-8. PubMed ID: 9186377
    [No Abstract]   [Full Text] [Related]  

  • 26. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PPI: new strategies for GERD].
    Hoshino E; Ishiyama A; Tsuchida T
    Nihon Rinsho; 2004 Aug; 62(8):1570-6. PubMed ID: 15344553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
    Furuta T; Sugimoto M; Shirai N; Ishizaki T
    Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An extensive metabolizer with recurrent ulcer responding to high dose of lansoprazole.
    Higuchi K; Tanabe S; Koizumi W; Nakayama N; Sasaki T; Nagaba S; Saigenji K; Katada N
    Hepatogastroenterology; 2004; 51(57):774-6. PubMed ID: 15143914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic studies on PPIs: look carefully at the country of origin.
    Savarino V; Savarino E; Dulbecco P
    Dig Liver Dis; 2006 Nov; 38(11):808-10. PubMed ID: 16945598
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cause and prevention of nocturnal gastric acid breakthrough].
    Adachi K; Kinoshita Y
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():779-83. PubMed ID: 11979888
    [No Abstract]   [Full Text] [Related]  

  • 33. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
    Giannini E; Romagnoli P; Fasoli A; Chiarbonello B; Malfatti F; Botta F; Risso D; Lantieri PB; Savarino V; Testa R
    Am J Gastroenterol; 2000 Oct; 95(10):2762-7. PubMed ID: 11051345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug interactions. Proton pump inhibitors. 1].
    Gleiter CH
    Internist (Berl); 1998 Aug; 39(8):874-5. PubMed ID: 9757395
    [No Abstract]   [Full Text] [Related]  

  • 35. [Erectile dysfunction and proton pump inhibitors].
    Grau Amorós J
    Med Clin (Barc); 2000 Apr; 114(12):478. PubMed ID: 10846705
    [No Abstract]   [Full Text] [Related]  

  • 36. Hydroxylation of lansoprazole in poor metabolizers of CYP2C19.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A
    Br J Clin Pharmacol; 2006 Mar; 61(3):361; author reply 361-2. PubMed ID: 16487234
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.
    Ohkusa T; Maekawa T; Arakawa T; Nakajima M; Fujimoto K; Hoshino E; Mitachi Y; Hamada S; Mine T; Kawahara Y; Nagai T; Aoyama N; Yoshida N; Tadokoro K; Chida N; Konda Y; Seno H; Shimatani T; Inoue M; Sato N
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1331-9. PubMed ID: 15932363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
    Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
    Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.